Preclinical Evaluation of CD64 As a Potential Target For CAR-T-cell Therapy For Acute Myeloid Leukemia

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xiaolei Sun ◽  
Guoling Wang ◽  
Shiyu Zuo ◽  
Qing Niu ◽  
Xiaoli Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
T Cell Therapy ◽  
Preclinical Evaluation ◽  
Potential Target ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

scholarly journals PS974 MODELING NKG2D-BASED CAR-T CELL THERAPY IN ANIMALS WITH ACUTE MYELOID LEUKEMIA

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 439
Author(s):  
M. Fontaine ◽  
E. Breman ◽  
B. Demoulin ◽  
S. Bornschein ◽  
J. Bolsée ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

scholarly journals CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia

2022 ◽  
Vol 11 ◽  
Author(s):  
Oren Pasvolsky ◽  
May Daher ◽  
Gheath Alatrash ◽  
David Marin ◽  
Naval Daver ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
Disease Free Survival ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet need. Building on growing knowledge of the interactions between leukemic cells and their bone marrow microenvironment, strategies to battle AML by immunotherapy are under investigation. In the current review we describe the advances in immunotherapy for AML, with a focus on chimeric antigen receptor (CAR) T cell therapy. CARs constitute powerful immunologic modalities, with proven clinical success in B-Cell malignancies. We discuss the challenges and possible solutions for CAR T cell therapy development in AML, and examine the path currently being paved by preclinical and clinical efforts, from autologous to allogeneic products.

scholarly journals Transformation of the acute myeloid leukemia to acute B cell lymphoblastic leukemia with CAR-T cell therapy: a case report and review of the literature

2021 ◽  
Author(s):  
Yanan Zhang ◽  
Fengan Liu ◽  
Xue Wang ◽  
Jiang Cao ◽  
Wei Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Lymphoid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

Lineage conversion is used to describe acute myeloid or lymphoid leukemia becomes the opposite at relapse.We report a 4-year-old child with acute myeloid leukemia who was converted to acute lymphoblastic leukemia at relapse and received chimeric antigen receptor T (cell) therapy for reference.

scholarly journals Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)

2019 ◽  
Vol 8 (2) ◽  
pp. 200 ◽  
Author(s):  
Susanne Hofmann ◽  
Maria-Luisa Schubert ◽  
Lei Wang ◽  
Bailin He ◽  
Brigitte Neuber ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Myeloid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients.

scholarly journals Transformation of the acute myeloid leukemia to acute B cell lymphoblastic leukemia with CAR-T cell therapy: a case report and review of the literature

2021 ◽  
Author(s):  
Yanan Zhang ◽  
Fengan Liu ◽  
Xue Wang ◽  
Jiang Cao ◽  
Wei Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Lymphoid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

Lineage conversion is used to describe acute myeloid or lymphoid leukemia becomes the opposite at relapse.We report a 4-year-old child with acute myeloid leukemia who was converted to acute lymphoblastic leukemia at relapse and received chimeric antigen receptor T (cell) therapy for reference.

scholarly journals Optimizing C-Type Lectin-like Molecule 1 (CLL-1) Directed CAR T Cell Therapy of Acute Myeloid Leukemia

2019 ◽  
Vol 25 (3) ◽  
pp. S167-S168 ◽  
Author(s):  
Pinar Ataca Atilla ◽  
Erden Atilla ◽  
Haruko Tashiro ◽  
Madhuwanti Srinivasan ◽  
Diogo Gomes Silva ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid

scholarly journals Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

2020 ◽  
Vol 10 ◽  
Author(s):  
Hui Zhang ◽  
Wen-Ting Gan ◽  
Wen-Ge Hao ◽  
Peng-Fei Wang ◽  
Zhuo-Yan Li ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Myeloid Leukemia ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Secondary Acute Myeloid Leukemia ◽  
Car T Cell Therapy ◽  
Car T ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document